{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T17:06:03Z","timestamp":1789146363671,"version":"build-2803163510"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.intimp.2026.117255","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T15:50:20Z","timestamp":1786377020000},"page":"117255","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["In vivo CAR-T therapy: The shift from ex vivo culturing to direct in situ immune reprogramming"],"prefix":"10.1016","volume":"187","author":[{"given":"Janani","family":"Gopalakrishnan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhagyashri","family":"Rathod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Puri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2026.117255_bb0005","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12967-024-06052-3","article-title":"From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy","volume":"23","author":"Pinto","year":"2025","journal-title":"J. Transl. Med"},{"key":"10.1016\/j.intimp.2026.117255_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105266","article-title":"Advancements and challenges in developing in\u00a0vivo CAR T cell therapies for cancer treatment","volume":"106","author":"Bui","year":"2024","journal-title":"eBioMedicine"},{"key":"10.1016\/j.intimp.2026.117255_bb0015","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41573-025-01291-5","article-title":"In vivo chimeric antigen receptor (CAR)-T cell therapy","volume":"25","author":"Bot","year":"2026","journal-title":"Nat. Rev. Drug Discov"},{"key":"10.1016\/j.intimp.2026.117255_bb0020","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40364-026-00899-y","article-title":"In vivo engineering of CAR-T cells: delivery strategies and clinical translation","volume":"14","author":"Gao","year":"2026","journal-title":"Biomark. Res."},{"key":"10.1016\/j.intimp.2026.117255_bb0025","doi-asserted-by":"crossref","first-page":"2558403","DOI":"10.1080\/21645515.2025.2558403","article-title":"In vivo CAR-T cell therapy: New breakthroughs for cell-based tumor immunotherapy","volume":"21","author":"Huang","year":"2025","journal-title":"Hum. Vaccines Immunother"},{"key":"10.1016\/j.intimp.2026.117255_bb0030","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/j.ymthe.2025.03.005","article-title":"From concept to cure: The evolution of CAR-T cell therapy","volume":"33","author":"Patel","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.intimp.2026.117255_bb0035","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.3390\/ijms23063154","article-title":"Preclinical Evaluation of CAR T Cell Function: In Vitro and In Vivo Models","volume":"23","author":"Si","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2026.117255_bb0040","doi-asserted-by":"crossref","unstructured":"Y. Kong, J. Li, X. Zhao, Y. Wu, L. Chen, CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity, Front. Immunol. Volume 15-2024 (2025). https:\/\/www.frontiersin.org\/journals\/immunology\/articles\/10.3389\/fimmu.2024.1519671.","DOI":"10.3389\/fimmu.2024.1519671"},{"key":"10.1016\/j.intimp.2026.117255_bb0045","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41577-025-01174-1","article-title":"In vivo CAR engineering for immunotherapy","volume":"25","author":"Li","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2026.117255_bb0050","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.tips.2025.11.001","article-title":"Autologous, allogeneic, in vivo CAR for autoimmune diseases","volume":"47","author":"Li","year":"2026","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.intimp.2026.117255_bb0055","article-title":"The Past","volume":"13","author":"Moretti","year":"2022","journal-title":"Present, and Future of Non-Viral CAR T Cells, Front Immunol"},{"key":"10.1016\/j.intimp.2026.117255_bb0060","doi-asserted-by":"crossref","first-page":"103828","DOI":"10.1016\/j.transci.2023.103828","article-title":"Leukapheresis for CAR-T cell production and therapy","volume":"62","author":"Pessach","year":"2026","journal-title":"Transfus. Apher. Sci."},{"key":"10.1016\/j.intimp.2026.117255_bb0065","doi-asserted-by":"crossref","first-page":"1613836","DOI":"10.3389\/fbioe.2025.1613836","article-title":"The potential of microfluidic cell analysis in CAR T cell therapy manufacturing","volume":"13","author":"Nikoniuk","year":"2025","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.intimp.2026.117255_bb0070","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1182\/blood-2016-02-629063","article-title":"CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date","volume":"127","author":"Park","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.117255_bb0075","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1080\/10428194.2017.1393668","article-title":"CAR T cell therapy for multiple myeloma: Where are we now and where are we headed?","volume":"59","author":"Ghosh","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.intimp.2026.117255_bb0080","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.intimp.2026.117255_bb0085","doi-asserted-by":"crossref","first-page":"1394057","DOI":"10.3389\/fonc.2024.1394057","article-title":"Chimeric antigen receptor T-cell therapy for aggressive B-cell lymphomas","volume":"14","author":"Hu","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.intimp.2026.117255_bb0090","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1053\/j.seminhematol.2020.07.005","article-title":"Improving CAR T Cell Therapy by Optimizing Critical Quality Attributes","volume":"57","author":"Reddy","year":"2020","journal-title":"Semin Hematol"},{"key":"10.1016\/j.intimp.2026.117255_bb0095","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","article-title":"Advances in the mechanisms and management of CAR T-cell toxicities","volume":"21","author":"Brudno","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.intimp.2026.117255_bb0100","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1016\/j.ymthe.2022.05.018","article-title":"Precision medicine: In\u00a0vivo CAR therapy as a showcase for receptor-targeted vector platforms","volume":"30","author":"Michels","year":"2022","journal-title":"Molecular Therapy"},{"key":"10.1016\/j.intimp.2026.117255_bb0105","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s13402-025-01056-7","article-title":"State of the art in CAR-based therapy: In vivo CAR production as a revolution in cell-based cancer treatment","volume":"48","author":"Esmaeilzadeh","year":"2025","journal-title":"Cell. Oncol"},{"key":"10.1016\/j.intimp.2026.117255_bb0110","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s40164-025-00725-5","article-title":"In vivo CAR-T cell engineering: concept, research progress, potential challenges and enhancement strategies","volume":"14","author":"Chen","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.intimp.2026.117255_bb0115","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.809754","article-title":"In-Vivo Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy","volume":"12","author":"Xin","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2026.117255_bb0120","doi-asserted-by":"crossref","first-page":"16017","DOI":"10.1038\/mtm.2016.17","article-title":"Production of lentiviral vectors","volume":"3","author":"Merten","year":"2016","journal-title":"Mol. Ther. Methods. Clin. Dev."},{"key":"10.1016\/j.intimp.2026.117255_bb0125","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.intimp.2026.117255_bb0130","doi-asserted-by":"crossref","first-page":"7333","DOI":"10.3390\/ijms25137333","article-title":"Viral and Non-Viral Systems to Deliver Gene Therapeutics to Clinical Targets","volume":"25","author":"Taghdiri","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2026.117255_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.seminoncol.2025.152430","article-title":"CAR-T cell therapy: A therapeutic strategy for cancer treatment","volume":"52","author":"Sharif","year":"2025","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.intimp.2026.117255_bb0140","article-title":"In vivo production of CAR T cell: Opportunities and challenges","volume":"12","author":"Song","year":"2025","journal-title":"Genes Dis."},{"key":"10.1016\/j.intimp.2026.117255_bb0145","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00005-010-0063-4","article-title":"Lentiviral vectors in gene therapy: their current status and future potential","volume":"58","author":"Escors","year":"2010","journal-title":"Arch. Immunol. Ther Exp. (Warsz)"},{"key":"10.1016\/j.intimp.2026.117255_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2019.107453","article-title":"Adeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery","volume":"207","author":"Nidetz","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2026.117255_bb0155","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70414","article-title":"Design Strategies for Novel Lipid Nanoparticle for mRNA Vaccine and Therapeutics: Current Understandings and Future Perspectives","volume":"6","author":"Li","year":"2025","journal-title":"MedComm"},{"key":"10.1016\/j.intimp.2026.117255_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.rechem.2026.103459","article-title":"Molecular design and therapeutic applications of polymeric nanoparticles for drug delivery: A comprehensive review","volume":"28","author":"Ahmed","year":"2026","journal-title":"Results Chem."},{"key":"10.1016\/j.intimp.2026.117255_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2026.126900","article-title":"Chemical noise and signal fidelity in stimuli-responsive drug delivery systems","volume":"697","author":"Rathod","year":"2026","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.intimp.2026.117255_bb0170","first-page":"2401","article-title":"CRISPR-Cas systems: Overview, innovations and applications in human disease research and gene therapy, Comput. Struct","volume":"18","author":"Xu","year":"2020","journal-title":"Biotechnol. J."},{"key":"10.1016\/j.intimp.2026.117255_bb0175","doi-asserted-by":"crossref","first-page":"13685","DOI":"10.3390\/ijms252413685","article-title":"Current Non-Viral-Based Strategies to Manufacture CAR-T Cells","volume":"25","author":"Gehrke","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2026.117255_bb0180","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1186\/s12951-026-04232-5","article-title":"In vivo CAR-T therapy: from molecular design to precision delivery","volume":"24","author":"Li","year":"2026","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.intimp.2026.117255_bb0185","article-title":"Delivery Platforms for In Vivo CAR-T Engineering","volume":"17","author":"Wang","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.117255_bb0190","doi-asserted-by":"crossref","first-page":"2614125","DOI":"10.1080\/10717544.2026.2614125","article-title":"Non-Viral CRISPR carriers: transient delivery with lasting effects","volume":"33","author":"Lummerstorfer","year":"2026","journal-title":"Drug Deliv."},{"key":"10.1016\/j.intimp.2026.117255_bb0195","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1126\/science.1220522","article-title":"Long-range ordered carbon clusters: a crystalline material with amorphous building blocks","volume":"337","author":"Wang","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.intimp.2026.117255_bb0200","doi-asserted-by":"crossref","DOI":"10.1002\/smtd.202401632","article-title":"Lipid Nanoparticles for Delivery of CRISPR Gene Editing Components","volume":"10","author":"Wu","year":"2026","journal-title":"Small Methods"},{"key":"10.1016\/j.intimp.2026.117255_bb0205","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41392-023-01309-7","article-title":"CRISPR\/Cas9 therapeutics: progress and prospects","volume":"8","author":"Li","year":"2023","journal-title":"Sig. Transduct. Target. Ther."},{"key":"10.1016\/j.intimp.2026.117255_bb0210","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13045-025-01759-2","article-title":"In vivo CAR cell therapy: from bench to bedside","volume":"18","author":"Xu","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.intimp.2026.117255_bb0215","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.3390\/ijms27041737","article-title":"In Vivo CAR-T Therapies\u2014A New Era of Programmable Immunity","volume":"27","author":"Pierini","year":"2026","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2026.117255_bb0220","doi-asserted-by":"crossref","first-page":"1383894","DOI":"10.3389\/fimmu.2024.1383894","article-title":"Universal CAR 2.0 to overcome current limitations in CAR therapy","volume":"15","author":"Schlegel","year":"2024","journal-title":"Front. Immunol"},{"key":"10.1016\/j.intimp.2026.117255_bb0225","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/ajh.25318","article-title":"A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents","volume":"94","author":"Short","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.intimp.2026.117255_bb0230","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3390\/biomedicines10010107","article-title":"Non-Integrating Lentiviral Vectors in Clinical Applications: A Glance Through","volume":"10","author":"Gurumoorthy","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.intimp.2026.117255_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2023.101139","article-title":"Lipid nanoparticles outperform electroporation in mRNA-based CAR T\u00a0cell engineering","volume":"31","author":"Kitte","year":"2023","journal-title":"Mol. Ther., Methods Clin. Dev"},{"key":"10.1016\/j.intimp.2026.117255_bb0240","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1158\/0008-5472.CAN-22-2155","article-title":"RNA therapeutics for improving CAR T cell safety and efficacy","volume":"83","author":"Schaible","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.intimp.2026.117255_bb0245","doi-asserted-by":"crossref","first-page":"1342193","DOI":"10.3389\/fgeed.2024.1342193","article-title":"Revolutionizing in vivo therapy with CRISPR\/Cas genome editing: breakthroughs, opportunities and challenges","volume":"6","author":"Macarr\u00f3n Palacios","year":"2024","journal-title":"Front. Genome Ed."},{"key":"10.1016\/j.intimp.2026.117255_bb0250","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41576-022-00541-1","article-title":"Prime editing for precise and highly versatile genome manipulation","volume":"24","author":"Chen","year":"2023","journal-title":"Nat Rev. Genet."},{"key":"10.1016\/j.intimp.2026.117255_bb0255","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00262-025-04278-8","article-title":"Unleashing CAR-T potential in solid tumors: overcoming intrinsic and extrinsic hurdles to improve therapy","volume":"75","author":"Zhang","year":"2026","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"10.1016\/j.intimp.2026.117255_bb0260","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1016\/j.ymthe.2021.07.010","article-title":"A comprehensive study of a 29-capsid AAV library in a non-human primate central nervous system","volume":"29","author":"Kondratov","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.intimp.2026.117255_bb0265","author":"Umoja Biopharma"},{"key":"10.1016\/j.intimp.2026.117255_bb0270","author":"Kite, A Gilead Company"},{"key":"10.1016\/j.intimp.2026.117255_bb0275","author":"Heng"},{"key":"10.1016\/j.intimp.2026.117255_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2026.124597","article-title":"When dose meets time: Understanding the toxicity of engineered nanomaterials and its implications for human risk assessment","volume":"402","author":"Rathod","year":"2026","journal-title":"Life Sci."},{"key":"10.1016\/j.intimp.2026.117255_bb0285","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/s13046-021-02148-6","article-title":"Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies","volume":"40","author":"Xiao","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2026.117255_bb0290","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.medj.2022.05.001","article-title":"Understanding CAR T\u00a0cell-tumor interactions: Paving the way for successful clinical outcomes","volume":"3","author":"Korell","year":"2022","journal-title":"Med"},{"key":"10.1016\/j.intimp.2026.117255_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.copbio.2024.103169","article-title":"In vivo gene delivery to immune cells","volume":"88","author":"Siebart","year":"2024","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.intimp.2026.117255_bb0300","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41586-024-08250-x","article-title":"Long-term lineage commitment in haematopoietic stem cell gene therapy","volume":"636","author":"Calabria","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2026.117255_bb0305","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1158\/2643-3230.BCD-23-0272","article-title":"The Fate(s) of CAR T-Cell Therapy: Navigating the Risks of CAR+ T-Cell Malignancy","volume":"5","author":"Abou-el-Enein","year":"2024","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.intimp.2026.117255_bb0310","article-title":"Enhancing the safety of CAR-T cell therapy: Synthetic genetic switch for spatiotemporal control","volume":"10","author":"Lu","year":"2026","journal-title":"Sci Adv"},{"key":"10.1016\/j.intimp.2026.117255_bb0315","article-title":"Regulation of CAR transgene expression to design semiautonomous CAR-T","volume":"32","author":"G\u0142owacki","year":"2024","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.intimp.2026.117255_bb0320","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","article-title":"T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy","volume":"30","author":"Ghilardi","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2026.117255_bb0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101250","article-title":"CAR-T cell manufacturing landscape\u2014Lessons from the past decade and considerations for early clinical development","volume":"32","author":"Dias","year":"2024","journal-title":"Mol. Ther.Methods Clin. Dev"},{"key":"10.1016\/j.intimp.2026.117255_bb0330","first-page":"1310002","volume":"4","author":"Colina","year":"2024","journal-title":"Current advances in experimental and computational approaches to enhance CAR T cell manufacturing protocols and improve clinical efficacy"},{"key":"10.1016\/j.intimp.2026.117255_bb0335","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1016\/j.ymthe.2025.04.006","article-title":"High-dimensional temporal mapping of CAR T cells reveals phenotypic and functional remodeling during manufacturing","volume":"33","author":"Cadinanos-Garai","year":"2025","journal-title":"Mol Ther"},{"key":"10.1016\/j.intimp.2026.117255_bb0340","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/s41551-026-01633-7","article-title":"Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancer","volume":"10","author":"Chen","year":"2026","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.intimp.2026.117255_bb0345","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jcyt.2025.05.010","article-title":"The next innovations in chimeric antigen receptor T cell immunotherapies for cancer","volume":"27","author":"Anupindi","year":"2025","journal-title":"Cytotherapy"},{"key":"10.1016\/j.intimp.2026.117255_bb0350","doi-asserted-by":"crossref","first-page":"1238535","DOI":"10.3389\/frtra.2023.1238535","article-title":"Promises and challenges of a decentralized CAR T-cell manufacturing model","volume":"2","author":"Shah","year":"2023","journal-title":"Front Transplant"},{"key":"10.1016\/j.intimp.2026.117255_bb0355","article-title":"CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.intimp.2026.117255_bb0360","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1186\/s12935-025-03938-0","article-title":"Advancements and challenges in CAR-T cell therapy for solid tumors: A comprehensive review of antigen targets, strategies, and future directions","volume":"25","author":"Zhu","year":"2025","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.intimp.2026.117255_bb0365","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.ccell.2022.08.008","article-title":"High-performance multiplex drug gated CAR circuits","volume":"40","author":"Li","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.intimp.2026.117255_bb0370","article-title":"From bench to body: In vivo CAR engineering in the clinic","volume":"6","author":"Li","year":"2025","journal-title":"Cell Rep. Med."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692601101X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692601101X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:08:56Z","timestamp":1789142936000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156757692601101X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":74,"alternative-id":["S156757692601101X"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117255","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vivo CAR-T therapy: The shift from ex vivo culturing to direct in situ immune reprogramming","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117255","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117255"}}